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Epidemiologic studies designed to evaluate the health significance of environmental chemicals are
compromised by the lack ofquantitative exposure data for individuals in exposed populations. Monitoring
data on levels of compounds in environmental media often represent the only information available, and
average population exposure isthereforetheonlyquantitativeparameterthatcanbecalculated. Biological
monitoring, i.e., measurements on cells, tissues or body fluids of exposed persons, has the objective of
defining the so-called "internal dose" or "effective dose" on an individual basis. Such measurements can
be used to ensure that current or past exposure does not entail unacceptable health risks, or can detect
potentially excessive exposure before the appearance of adverse health effects. Results obtained through
this approach can be interpreted on an individual basis and also used to estimate for that individual the
amount of chemical absorbed during a specific time interval or the amount bound to critical sites. They
may also be useful for characterization of community exposure by analyzing results obtained in groups
of individuals within the general population. In this respect, biological monitoring data complement
environmental measurements but have certain advantages in estimating health risks. Most importantly,
the data obtained are more directly related to adverse effects and thus provide a better estimate of risk
thanambientmonitoring. Biological monitoringalsotakesintoaccountabsorptionbyallroutes, integrates
exposure from all sources, and therefore can be used as a basis for estimate of total risk from multiple
chemicals.
Strategies for Exposure Monitoring
Two categorical types ofmeasurements can be made
in biological monitoring: measurements of levels of
chemicals, their metabolites and/or derivatives in body
fluids or excreta and measurements of biological re-
sponses such as mutation, sister chromatid exchange,
chromosome aberrations, etc., in cells and tissues of
exposed individuals.
Quantification ofchemicals in body fluids (e.g., blood,
breast milk, saliva, semen) or in excreta has been car-
ried out by direct chemical analysis, immunologic ana-
lysis, or can be inferred from results of bioassays for
mutagenicity. Most of the existing chemical methods
and available datarelate tooccupational exposure, since
such measurements have been used in occupational hy-
giene programs for many years. Immunoassays and
bioassays are more recent developments that have as
yet found only limited application. With the recognition
that most genotoxic chemicals require metabolic acti-
vation to electrophilic forms in order to express their
effects, an additional strategy for chemical dosimetry
has developed based upon the detection and quantifi-
cation of covalently bound derivatives formed between
activated chemicals and cellular macromolecules such as
nucleic acids and proteins. Immunologic and chemical
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analyticalmethodshavebeendevelopedforthispurpose
which are sufficiently sensitive to detect the conse-
quences ofambient exposure in the workplace and gen-
eral environment.
Prevention of excessive exposure to chemicals in in-
dustry has been approached traditionally by setting
standards for the concentration of compounds in am-
bient air. Air monitoring has therefore constituted the
principalmeans ofassessingexposure, anapproachthat
obviously takes into account only exposure via the pul-
monary route and cannot estimate total exposure. Over
the past two decades, analytical methods have been
developed for many compounds representing a variety
of chemical classes to which people are exposed, prin-
cipally in the workplace. Lauwerys (1) has summarized
these methods from the perspective oftheir usefulness
in biological monitoring programs and described a total
of 69 chemicals for which analytical methodology was
considered to be sufficiently well developed for appli-
cation in worker surveillance programs. Lauwerys (1),
as well as Baselt (2) and Linch (3), summarized the
analytical methodology as well as additional pertinent
information including representative values for each of
the chemicals in body fluids.
In addition to theiruse inmonitoring programs inthe
workplace, a few of these methods have also been ap-
plied to population studies involving large numbers of
subjects. For example, chlorinated hydrocarbons have
been extensively studied with respect to their storageWOGAN AND GORELICK
and accumulation in adipose tissue and other body com-
partments. Hayes (4) summarized the literature con-
cerning levels of DDT and its derivatives in adipose
tissue and other body compartments in large numbers
of subjects studied over a period of two decades. In a
related area, analysis ofhuman milkhas been employed
to determine exposure to chlorinated pesticides (5) and
to polychlorinated biphenyls (6,7).
With reference specifically to environmental carcin-
ogens and mutagens, the monitoring field is in a more
primitive state of development. The main focus of re-
search has been on the development ofanalytical meth-
ods for detection of carcinogens that can occur as
contaminants offood, and consequently most ofthe ex-
isting methods were intended for the purpose of food
analysis. Methods have been published for some N-ni-
troso compounds, polycycic aromatic hydrocarbons, ar-
omatic amines, vinyl chloride, and mycotoxins. The
suitability ofthese methods for analysis ofmedia other
than food has not usually been evaluated, and in many
instances they are impracticalforanalysis oflarge num-
bers of samples.
A larger number of analytical methods are available
for aflatoxins than for any other class ofcarcinogen. In
this case, some methods originally developed for anal-
ysis of oilseeds and grains have been adapted for anal-
ysis of edible tissues and milk of animals in order to
minimize human exposure through residues ofthe par-
ent compounds or metabolites, and have also been ap-
plied in analysis oftissue ofpeople suspected ofhaving
been exposed to aflatoxins.
In studies of the putative etiologic role of aflatoxins
in cases of Reye's syndrome, an acute highly fatal dis-
ease of children, aflatoxin B1 (AFB1) was detected in
samples of liver, stool, brain, and kidney at levels in
the order of100 ng/gthrough application ofathin-layer
chromatographic (TLC) method with fluorescence de-
tection (8,9). These results were extended and sub-
stantiated in more recent studies in which HPLC
separation with fluorescence detection was used (10-
12). Aflatoxinshavealsobeendetectedinhumantumors
oftheliver(13,14) andlung(15)withTLCmethodology.
Studies in human populations consuming aflatoxin-
contaminated peanut butter revealed the presence of
aflatoxin M1 in urine, as detected by TLC analysis (16),
and aflatoxins were also found in the urine of Sudanese
children suffering from kwashiorkor examined by HPLC
analysis (17). Chemical screening methods fordetection
of aflatoxin and metabolites in human urine (18) and
serum (19) have been reported.
The rapidly developing field of immunoassay has up
to now principally been applied to the detection of co-
valent adducts of carcinogens with DNA, as will be dis-
cussed subsequently. However, methods based on ra-
dioimmunoassays have been reported for two carcino-
gens. Johnson et al. (20) developed aradioimmunoassay
procedure for 4-acetamidobiphenyl, a metabolite ofthe
carcinogen 4-aminobiphenyl, in urine. Rabbit poly-
clonal antibodies with high affinity (2.8 x 108 L/mole)
were produced which were capable ofdetectingthe me-
tabolite at levels of about 1 ng (4.8 pmole) in human
urine.
Sizaret et al. (14) similarly developed rabbit poly-
clonal antibodies which detected not only aflatoxin B1
butalsocross-reactedwithvariousaflatoxinmetabolites
including M1, the principal urinary excretory product
discussed above. The radioimmunoassay developed us-
ing these antibodies was capable of following urinary
metabolites ofaflatoxin administered to rats at doses of
600 pmole or less. The authors thus propose that the
assay would be suitable for use in human population
studies.
Covalent Adducts as Dosimeters
The rationale underlying the strategy ofchemical do-
simetry by determining levels ofderivatives covalently
bound to cellular macromolecules is based on current
understanding of the mode of action of genotoxic car-
cinogens and mutagens. Chemicals that are active as
carcinogens and mutagens have electrophilic properties
or are metabolically converted into electrophiles. These
reactive derivatives undergo attackbynucleophilic cen-
ters in nucleic acids and proteins, resulting in the for-
mation ofcovalent adducts. Particular attention has been
paid to DNA adducts, since these are thought to rep-
resent initiating events leading to mutation and/or ma-
lignant transformation. Covalent adducts formed in RNA
and proteins have no putative mechanistic role in car-
cinogenesis, but may relate quantitatively to total ex-
posure and activation, and could therefore contribute
to dosimetry ofboth exposure and activatingcapability.
Covalent nucleic acid adducts have differing levels of
stability, some being removed spontaneously through
chemical depurination, whereas others are removed en-
zymatically, in the process ofDNA repair. A small pro-
portion remain in DNA over long periods of time. In
the few experimental models in which appropriate mea-
surements have been made, adducts removed sponta-
neously or enzymatically from DNA are excreted in
urine in amounts reflective of total binding levels. In
contrast, protein adducts are stable over the life span
of the protein, and therefore accumulate with multiple
exposures.
These properties collectively form the basis for sev-
eral complementary approaches to development of
chemical dosimeters, providing different kinds ofinfor-
mation. Measurements of DNA adducts in situ in the
DNA of cells should give the most direct evidence of
genotoxic exposure; excretionofDNAadducts (orprod-
ucts ofthem) in urine should give an indication oftotal,
recent exposure; whereas protein adducts should pro-
vide an index oftotal exposure integrated over the life-
span of the target proteins.
Protein Adducts
Ehrenberg and Osterman-Golkar (21) reviewed the
rationale and technical requirements for the use ofpro-
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tein alkylation for detecting mutagenic agents. Impor-
tant among these requirements is that exposure must
result in the formation ofstable covalent derivatives of
amino acids for which assay methods of adequate sen-
sitivity and specificity can be devised. Further, the tar-
get protein should be found in easily accessible fluids
(e.g., blood) and should be present in concentrations
adequate to provide sufficient material for analysis.
Among the amino acids likely to be alkylated following
exposure are cysteine, histidine, the N-terminal amino
acid of protein, and lysine. Although any protein could
in principle be used for monitoring of alkylated deriv-
atives, hemoglobin was suggested by Osterman-Golkar
et al. (22) as a suitable dose-monitoring protein, and
nearly all of the relative literature concerns studies of
hemoglobin alkylation.
Osterman-Golkar et al. (22) established the stability
of alkylated residues in hemoglobin modified by ethyl-
ene oxide or dimethylnitrosamine, and the equivalence
ofthe half-life ofalkylation levels produced by a single
dose to the life span of hemoglobin in the mouse. Al-
kylation of hemoglobin in mice treated with vinyl chlo-
ride was described by the same investigators (23).
Segerback et al. (24) further characterized the experi-
mental model in mice treated acutely and chronically
with the direct-acting alkylating agent methyl meth-
anesulfonate in which they demonstrated the validity
ofthe steady-state level ofalkyl residues in hemoglobin
as a measure of chronic repeated exposure.
Subsequently, Calleman et al. (25) carried out astudy
of hemoglobin alkylation in people occupationally ex-
posed to ethylene oxide. Blood samples were obtained
from persons exposed to doses ofethylene oxide estab-
lished through continuous air-monitoring. Hemoglobin
was analyzed for the presence of N-3-(2-hydroxy-
ethyl)histidine by mass spectrometry and by ion-ex-
change amino acid analysis. The authors concluded that
the hemoglobin alkylation values accurately reflected
exposure, and were ingood agreement withearlierdata
derived for ethylene oxide in the mouse.
Pereira and Chang (26) surveyed the ability of car-
cinogens and mutagens representing a broad spectrum
of chemical classes to bind covalently to hemoglobin in
rats. Animals were dosed with "4C-labeled test com-
pounds at levels of0.1 to 10 ,umole/kg body weight and
blood was collected 24 hr later. Covalent binding was
determined by analysis ofpurified hemoglobin for cov-
alently bound radioactivity. All carcinogens/mutagens
were found to forn covalent adducts with hemoglobin,
buttheabilitytodosovaried overawiderange (binding
index from 10 to 3322). It should be emphasized that
the magnitude ofthis index is not reflective ofpotency
as carcinogens for the rat, but when compounds were
administered at more than one dose, the hemoglobin
binding index was also dose related.
In order for protein alkylation to be useful as a mon-
itoring procedure, reliable dose-response relationships
between exposure dose and production ofalkylated amino
acids must be established. This requirement has been
satisfied for the exposures studied to data, all of these
experiments having been carried out in animals rather
than in man. Thus, GC-MS determination of the pro-
duction of S-methylcysteine in rat hemoglobin, follow-
ing IP treatment with methyl methanesulfonate, showed
that the alkylated amino acid was linearly related to
dose (27). As noted above, experiments by Segerback
et al. (24) showed thatthe degree ofalkylation ofhemo-
globin in mice exhibited a linear dependence on the
quantity ofmethyl methanesulfonate injected. For eth-
ylene oxide a virtually linear relationship was observed
between dose and production of N-3'-(2-hydroxy-
ethyl)histidine in hemoglobin, in experiments in which
the alkylating agent was administered by inhalation at
doses of 1 to 100 ppm (30 hr/week for 2 yr) (28).
Other agents for which dose-response relationships
have been established include the following: 4-amino-
biphenyl(29), whichdisplayed alinearhemoglobinbind-
ing response from 0.5 to 5000 jxg/kg; trans-4-dimethyl-
aminostilbene (30), where total binding to rat hemo-
globin increased linearly over a 105-fold dose range;
chloroform (31), which showed alinearbindingfrom 0.1
to 100 mmole/kg in rat and mouse hemoglobin. Only for
dimethylnitrosamine (27) was the dose response nonlin-
ear over an IP dose range of0 to 400 mmole/kg in rats.
It can thus be concluded that the amount ofalkylated
hemoglobin will be directly related to the erythrocyte
dose of active alkylating agent, and the observed re-
lationship between hemoglobin alkylation and exposure
dose in animal experiments has also indicated that
erythrocyte dose and exposure dose are directly re-
lated. The observation ofhemoglobin alkylation can be
considered an indication ofgenotoxic risk, however, only
when it hasbeen shownthat such alkylations correlated
with reactions at the target DNA site, i.e., that the
erythrocyte dose is directly related to the target dose.
Comparison ofthe amounts of DNA and hemoglobin
binding products have been made for a variety of ra-
dioactive alkylating agents. Vinyl chloride (23) and di-
methylnitrosamine (22) have relatively short-lived
metabolites, so the doses received by organs located
distant from the liver represented only a small fraction
of the liver dose, whereas ethylene oxide was more
uniformly distributed. In the rat, observed levels of
alkylation of guanine in liver DNA and testis DNA by
ethylene oxide were about 150% and 50%, respectively,
of values expected from the degree of alkylation of
hemoglobin (28). Similarly, in the mouse (32) the extent
ofguanine alkylation inliver, spleen and testis deviated
bynomorethantwofoldfromthe amountexpectedfrom
hemoglobin alkylation. Thus the degree ofalkylation of
DNA could be estimated approximately fromthe eryth-
rocyte dose for ethylene oxide.
Further support for the use of hemoglobin (or other
protein) alkylation as an indication ofDNA-binding has
come from the work ofNeumann (30) who showed that
the dose response of binding of trans-4-dimethylami-
nostilbene to plasma proteins and to hemoglobin was
proportional to the dose-response for binding to liver
DNA. Similarly, Pereiraet al. (33) have illustrated that
the dose-response curves for the binding of 2-acetyl-
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aminofluorene to hemoglobin and rat liver DNA are
closely related over a large dose range.
Thus in some instances, it seems possible to predict
DNA-binding by means of determinations of protein
binding, and therefore detection of the latter may be
taken as an indication of a genotoxic risk. OPne ofthe
mostimportant questionsremainingis howriskis quan-
titatively related to extent of DNA binding.
DNA Adducts
Two experimental avenues are available to obtain in-
formation on levels of DNA adducts formed through
carcinogen activation. Measurements can be made of
DNA adducts in cells ofan accessible tissue (e.g., white
blood cells, biopsy, or autopsy samples). Providing that
the chemical nature and stability of the DNA adducts
for the compound of interest had been fully character-
ized, qualitative as well as quantitative identification of
adduct levels could provide for that individual not only
an indication of exposure history but also of his capa-
bility to activate the carcinogen to DNA-binding forms.
It is well established that nearly all carcinogens form
complex spectra of DNA adducts, involving covalent
binding to various nucleophilic sites on all four DNA
bases as well as the phosphate residues ofDNA. Thus,
from a qualitative viewpoint, detection of all DNA ad-
ducts derived from even a single carcinogen presents a
very complex analytical challenge. Quantification ofad-
duct levels is complicated further by the removal of
adducts from DNA by chemical or enzymatic processes
atdifferentrates, evenwithinthesamecell. Theserates
canalsovarysubstantiallyfromonecelltypetoanother.
Most available information of DNA adducts in ex-
perimental systems has been obtained through the use
of physicochemical or radiochemical methods of detec-
tion. Usefulness of these methods for detection in hu-
man monitoring is limited bytheirrelative insensitivity
andinapplicability, respectively. However, immunolog-
icaltechniques arebeingdeveloped which have promise
of utility in detecting DNA adducts in people exposed
toenvironmentalcarcinogensunderambientconditions.
The determination of carcinogen-DNA adducts by im-
munologic procedure has certain advantages over other
techniques. The sensitivity is frequently better than
that obtainable with radiolabeled carcinogens (which are
useful only for experimental purposes in any event).
Antibodies are specific for particular three-dimensional
structures and can be used to probe the conformation
ofunknown adducts on DNA. Immunological assays are
rapid, highly reproducible and can be used in situations
where the cost or availability of radiolabeled carcino-
gens would be prohibitive. The high sensitivity and ca-
pability of detecting nonradioactive adducts would
therefore suggest a use in monitoring ofhuman tissues.
In addition, immunologic techniques can be applied to-
gether with morphologic procedures (electron micros-
copy and immunofluorescence) to localize adducts in
particular cells, subcellular compartments, or DNA
molecules. Current methods for detecting adducts in
DNA are summarized below.
Asecond approachtomonitoringDNAadductsisalso
being explored, taking advantage of the fact that ad-
ducts removed from cellular DNA (and also from RNA)
are excreted inurine. Theirdetection andmeasurement
of excretion rates would, in principle, provide infor-
mation on (recent) exposure history ofthe subject, and
possibly also indications of that individual's capability
for DNA repair. Thus, studies ofurinary excretions of
adducts would provide data complementary to mea-
surement of adduct levels in cellular DNA in the same
individual.
The value of DNA adduct measurements in the do-
simetry of genotoxic exposure will depend upon the fi-
delitywithwhichtheyreflectexposurelevels. Available
information suggests that, in some experimental animal
models, levels of DNA adducts in tissues are indeed
reflective ofcarcinogen doses. Pegg and Perry (34) de-
termined levels of7-methylguanine in DNA ofliver(the
target organ) in rats killed 3 hr after a single dose of
dimethylnitrosamine. They found that levels of this
methylated base were linearly related to intraveneous
or oral doses of the carcinogen over a dose range of 1
to 105 ,ug/kgbodyweight. Similarly, Appleton et al. (35)
found that totalAFB1 adduct levels in DNA (and RNA)
of the livers of rats injected with the carcinogen and
killed 1 hrlaterwere linearly related toAFB1 dose over
the range of 10 to 1000 ng/kg body weight.
The binding ofbenzo(a)pyrene (BaP) to nucleic acids
of target and nontarget tissues has been studied by a
number of investigators. Lutz et al. (36) administered
the carcinogen by single injection to rats over the dose
range 40 pLg/kg to 4 mg/kg body weight. The animals
were killed 50 hr afterdosingand totalcarcinogenbind-
ing to liver DNA was determined. The dose-response
relationship was found to be linear up to 1 mg/kg and
nonlinear at higher doses. Dunn (37) also measured lev-
els of DNA adducts derived from BaP in the DNA of
target (stomach) and nontarget (liver) organs of mice,
and found direct proportionality between binding level
and dose over a wide dose range (10' to 103 g/mouse).
The relationship appeared to be linear over most ofthe
dose range, but Stowers and Anderson (38) report non-
linearity in other experimental models.
Relationships between concentrations of covalently
bound 14C-formaldehyde in the DNA ofthe respiratory
epithelium and air levels of the carcinogen have been
investigated in rats exposed at levels of 0.3 to 15 ppm
(39). At concentrations of2 ppm or higher, the level of
DNA modification was directly proportional to the air-
born carcinogen level, but below 2 ppm the amount of
DNA binding was less than proportional to dose.
Collectively, these data suggest that DNA adduct
levels can reflect carcinogen exposure, although the
quantitative relationships between the two parameters
will need to be established in a larger number of ex-
perimentalmodels before generalizations canbe drawn.
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DNA Adducts and Carcinogenesis
Replication of DNA soon after carcinogen-induced
DNAdamageisimportantformutagenesis, cellcurvival
(40), and in vitro transformation (41). Available data
suggest that DNA replication after carcinogen treat-
ment in vivo is also important in the development of
cancer (42-44). It is possible that the initiation of car-
cinogenesis may result from replication of carcinogen-
damaged DNA, which presumably fixes alesionin DNA
as amutation. Thus, to exert its mutagenic and possibly
acarcinogenic effect, a DNAadduct mayneed toremain
in DNA until DNA replication occurs. Consistent with
this idea, the persistence in DNA of some adducts (which
may be premutagenic lesions) correlates with the in-
duction of cancer, as indicated by several lines of
evidence.
People who suffer from syndromes characterized by
deficiencies inDNArepair are prone tothedevelopment
of cancers (45). Examples of such syndromes include
xeroderma pigmentosum (46), Fanconi's anemia (47),
and ataxia telangiectasia (48,49). Cultured cells from
people with DNA repair deficiencies do not remove DNA
modifications and are hypersensitive to the induction of
mutation after chemical treatment (40,50,51). The time
interval between carcinogen treatment and DNA syn-
thesis is inversely related to the induced mutation fre-
quency in repair-efficient chemically treated cells,
whereas this interval is inconsequential to induced mu-
tation frequency in repair-deficient cells (50).
Species susceptible to the tumorigenic effects of a
chemical and species resistant to the same effects form
qualitatively similar DNA-adduct profiles in many or-
gans. Examples include DNA adducts formed after
treatment with aflatoxin B1 (in male rat and mouse,
kidney and liver) (52,53), dimethylbenzanthracene
(DMBA) in female Swiss and C57BL mouse skin (54)
and benzo(a)pyrene in male Swiss mice and Wistar rat
skin(55). Amongalladductsformed, specific DNAmod-
ifications can persist in DNA. While additional sites in
DNA are modified, persisting small and bulky lesions
formpredominantly atthe O6, N2, and C8 atoms ofguan-
ine. Although N7-guanine modification generates a pos-
itive charge in the imidazole ring, rendering the
glycosidic bond labile, neutralization of the positive
charge by fission of the imidazole ring stabilizes the
modified guanine in DNA. Therefore, the respective
formamidopyrimidine derivatives of N7-modified guan-
ine may also persist in DNA.
Although qualitatively similar adducts form in sen-
sitive and resistant species, in many cases a greater
total amount of adducts is found in target organ DNA
ofsensitive species. Persistent adducts and the respec-
tive target organs are summarized in Table 1. Target
organs in which more adducts persist and nontarget
organs where fewer adducts persist are listed in Table
2.
The quantitative difference in adduct persistence in
target organDNAofsensitive andresistantspecies may
be attributable to a number of possible mechanisms.
Different organs in one animal or the same organ in
different speciesorevendifferentcelltypesinoneorgan
mightpossessdifferentcapacities forspecificrepairpro-
cesses; those organs or cells with minimal repair ca-
pacities would be least efficient in removing certain
adducts. Indeed, greater persistence of DMH-induced
06-methylguanine in DNA has been demonstrated in
nonparenchymal cells (70) that are deficient in repair
activity for this lesion (69) and in which DMH-induced
tumors arise.
Furthermore, different organs in one animal or the
same organ in different species may vary in metabolic
activation capacity (including types and extents of re-
action). Therefore, target organ DNA may be modified
to a greater extent due to relatively high activating
enzyme levels or relatively low levels of enzymes for
competing detoxification pathways. If adducts are re-
moved at a constant rate, greater initial adduct levels
would be reflected in longer adduct persistence. Alter-
natively, high initial amounts of adduct might saturate
constitutive repair processes, leading to enhanced
persistence.
Although a positive correlation is often observed be-
tween adduct persistence and sensitivity to tumor in-
duction for different species, differences in adduct
persistence do not correlate well with the differences
in carcinogenicity of one compound in different strains
ofthe same species. Instanceswheremoreadductsform
or persist in resistant rather than sensitive species or
strains are noted in Table 3. In some of these studies
covalent modification was monitored for a relatively short
interval after dosing, especially since the level ofmod-
ification is still increasing at 24 hr after dosing (78). It
is also significant that DNA was analyzed for total cov-
alent modifications instead of for specific lesions. Mea-
surement ofpersistence oftotal lesions may not detect
thepersistenceofaminorbutimportantlesion(aswould
be the case with 06-alkylguanine). Finally, the relative
rate ofspecific adduct removal rather than the absolute
amount ofpersistent adduct may be important for sus-
ceptibility to tumor formation. For instance, although
higher levels of adducts form in the liver (a nontarget
organ) compared to the mammary gland (the target or-
gan), DanielandJoyce(77) observed 70% DMBAadduct
removal from liver DNA but essentially total persist-
ence of DMBA adducts in the rat mammary gland.
In addition to indicating potential target organs for
tumorigenesis, the quantityofadductsinDNAmayalso
indicate the relative carcinogenic potency of different
chemicals. The extent of covalent binding of polycyclic
aromatichydrocarbons toDNAinmouse skincorrelates
in a positive manner with carcinogenic potency (79) and
with tumor initiating activity (80). Covalent binding of
PAH to DNA in mammalian cells also correlates with
carcinogenic potency (81).
Lutz (82) reviewed the correlation between covalent
modification ofDNA and carcinogenicity for a wide range
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of chemical classes, and discusses the covalent binding
index (CBI), defined as
CBI damage to DNA
dose
micromole chemical bound per mole nucleotides
millimole dose/kilogram body weight
The CBI is determined when rodents are treated with
radiolabeled chemicals, liver DNA is isolated at the time
of maximum binding to DNA and covalent modification
is quantified by liquid scintillation counting. The CBI is
correlated with the rodent hepatocarcinogenicity of at
least 16 chemicals from different classes.
The value of the CBI as a quantitative index of gen-
eral carcinogenicity is, however, limited by a relatively
high rate offalse positives, especially with direct acting
alkylating agents such as sulfonates and some nitroso
derivatives. The weakness of this index may be ex-
plained by the fact that there are many factors which
do not enter into the CBI calculations but on which the
CBI depends. These factors, such as species, strain,
dose response, time between dose and DNA isolation,
method of DNA isolation, metabolic state of test ani-
mals, target organ, and cell specificity, probably vary
with each chemical. The value of the CBI as an index
ofcarcinogenicity iscompromised for two additional rea-
sons in particular. First, this index reflects total cova-
lent modification ofDNA. It ispossible thatonlyspecific
DNA modifications, as discussed above, are biologically
relevant to carcinogenesis, a relationship that the CBI
Table 1. DNA adduct persistence associated with target organ sensitivity.
Species and organ
in which adduct Doses
Persistent persists and tumor
Carcinogena adducta develops Number Route Persistenceb References
AFBI AFB,-FAPyC Rat liver 10 IP 2 weeks (53,56)
Aromatic amines
N-OH-AAF AF-C8-dG Rat mammary 1 IP 4 weeks (57)
AF-C8-dG gland
AAF-N2-dGd Rat liver 1-4 Oral 8 weeks (58)
N-OH-1-NA 1-NA-06-dG Rat skin 1 SC 7 days (59)
Dog urinary
2-NA 2-NA-C8-dG bladder 1 Oral 7 days (60)
BZ ABZ-C8-dG Mouse liver 7 days In water 7 days (61)
DMAB or AB AB-C8-dG Mouse liver 1 IP 21 days (62)
BaP BPDE-I-N2-dG Swiss mousee 1 Topical 3 weeks (55,63)
epidermis
BALB/c mouse skin 1 Topical 4 weeks (64)
SENCAR mouse
epidermis and
basal epidermal
(+)BPDE -I BPDE-I-N2-dG cells 1 Topical 72 hr (65)
MCPP-N2-dG,
MCPP MCPP-dA Mouse skin 1 IM 14 days (66,67)
A/J and C3H mou-
3-MC (total) sef lung 1 IV 28 days (68)
Alkylating agents
DMH Me-06-G Rat liver nonparen- 2 Oral 48 hr (69)
chymal cells 28 Oral 4 weeks (70)
MNU Me-N7-FAPy Rat bladder 1 IU 21 days (71)
ENU Et-06-G Rat brain 1 IP 10 days (72)
DEN Et-04-T Rat hepatocytes 77 Oral 11 weeks (73)
aAAF-N2-dG, 3-(deoxyguanosin-N2-yl)-acetylaminofluorene; AB, aminoazobenzene; AB-C8-dG, N-(deoxyguanosin-8-yl)-4-aminoazobenzene;
ABZ-C8-dG, N-(deoxyguanosin-8-yl)-N'-acetylbenzidine; AFB1, aflatoxin B1; AFB,-FAPy, 2,3-dihydro-2-(N5-formyl)-2',5',6'-triamino-4'-oxo-
N6-pyrimidyl-3-hydroxyaflatoxin; AF-C8-dG, N-(deoxyguanosin-8-yl)-2-aminofluorene; BaP; benzo(a)pyrene; (+)BPDE-I, (+)-7R,8S-dihy-
droxy-9R,lOR-epoxy-7,8,9,10-tetrahydrobenzo(a)pyrene; BPDE-I-N2-dG, 100-(deoxyguanosin-N2-yl)-7,3,8a,9cx-trihydroxy-7,8,9,10-tetrahydro-
benzo(a)pyrene; BPDE-I-tetrol, (t )-7,,8a,9a,10(a or ,3)-tetrahydroxy-7,8,9, 10-tetrahydrobenzo(a)pyrene; BZ, benzidine; DEN,
diethylnitrosamine; DMAB, N,N-dimethyl-4-aminoazobenzene; DMBA, dimethylbenzanthracene; DMH, 1,2-dimethylhydrazine; ENU, ethyl-
nitrosourea; Et-06-G, 06-ethylguanine; Et-04-T, 04-ethylthymidine; MCPP, 15,16-dihydro-11-methyl-cyclopenta[a]phenanthren-17-one; MCPP-
dA, an unidentified adduct between an MCPP metabolite and deoxyadenosine; MCPP-N2-dG, 1-(deoxyguanosin-N2-yl)-1,2,3,4-tetrahydro-2,3,4-
trihydroxy-15,16-dihydro-11-methylcyclopenta(a)phenanthren-17-one; Me-06-G, 06-methylguanine, Me-N7-FAPy, N-methyl-N5-formyl-2,5,6-
triamino-4-hydroxypyrimidine; MNU, methylnitrosourea; N-OH-AAF, N-hydroxy-acetylaminofluorene; N-OH-1-NA, N-hydroxy-l-naphthy-
lamine; PAH, polycyclic aromatic hydrocarbon; 1-NA-06-dG, N-(deoxyguanosin-O -yl)-l-naphthylamine; 2-NA, 2-naphthylamine; 2-NA-C8-dG,
N-(deoxyguanosin-C8-yl)-2-naphthylamine; 3-MC, 3-methylcholanthrene.
bPersistence indicates time from the first dose. Time noted was the last time point in the study.
'The adduct inequilibrium with AFB,-FAPy is also persistent.
dThis adduct is detected only in male rat liver, is found in increasing amounts with continued dosing, and persists only as long as dosing
continues.
'In this case, the strain of mouse is important. See Table 3.
fIn this case, the strain of mouse is important. See Table 2.
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Table 2. DNA adduct levels and persistence associated
with target organ sensitivity.
Nontarget tissues or
Target tissues or or- organ where fewer
gan where adducts adducts form and/or
Carcinogena persista persist References
AFB1 Male rat liver Male rat kidney (53,56)
Male rat liver Male mouse liver
N-OH-AAF Male rat liver Female rat liver, rat (58)
kidney
2-NA Dog urinary bladder Dog liver (60)
DMAB and Mouse liver Rat liver (62)
ABb
BaP Male or female Male rat skin (55)
mouse skin
MCPP TO mouse skin TO mouse liver (66)
3-MC A/J and C3H DBA and C57BL (68)
mouse lung mouse lung or A/J
and C3H mouse
liver
DMH Male rat nonparen- Male rat hepatocytes (70)
chymal cells
ENU Rat brain Rat liver (72)
DEN Male rat Male rat nonparen- (73)
hepatocytes chymal cells
aSee Table 1 for abbreviations and the corresponding persistent
DNA adduct.
bAB and its N-methyl and N,N-dimethyl derivatives are tumori-
genic in mice while only the methylated derivatives are hepatocar-
cinogenic inrats. AB-C8-dG isthe majoradduct formed and itpersists
in mouse liver DNA after AB or DMAB treatment. The same adduct
forms only in very low amounts in rat liver DNA after DMAB or
MAB treatment.
would obscure. Second, the CBI is based on the initial
formation of adducts whereas initiation of carcinogen-
esis may be a consequence of adduct persistence, also
as discussed above.
Methods for Detecting Carcinogen-
DNA Adducts
Methods of varying sensitivities exist to measure
DNA-carcinogen adducts. Many of these methods are
applicable for the detection of adducts in DNA from
human tissues, as discussed below. To facilitate com-
parison ofthe various techniques, assays are presented
fordetectionofthemajorBaP-DNAadduct, 10,-(deoxy-
guanosin-N2-yl)-7p,8ao,9a-trihydroxy-7,8,9-tetrahydro-
benzo(a)pyrene (BPDE-I-N2-dG), since most available
assayshave beenused to detectthis PAH-DNA adduct.
A summary ofthe assays and their sensitivities is found
in Table 4. It is important to note that the sensitivity
of an assay as defined here depends on the amount of
DNA assayed as well as the rate ofmodification ofthat
DNA. In otherwords, themost sensitive assayrequires
the least DNA, modified at the lowest level. Both fac-
tors must be evaluated for each method.
Ultraviolet absorbance (at 254 nm or other wave-
lengths, depending on the modifying carcinogen) in line
with RP HPLC is sensitive to the detection of approx-
imately hundreds of picomoles (generally less than 1
pLg) of adduct. This approach is generic for many car-
cinogen-DNA adducts due to the strong absorbance of
DNA bases at 254 nm. Although this method is in prin-
ciple applicable to the detection ofadducts in DNAfrom
people, compared with other available methods, it is
relatively insensitive.
Rahn and his colleagues (84) developed an assay for
the detection of BaP-DNA adducts by fluorescence.
They hydrolyze BPDE-DNA in 0.12 N HCl for 6 hr at
80°C to release ( )-73,B8a,9a,10-tetrahydroxy-7,8,9,10-
tetrahydrobenzo(a)pyrenes (BPDE-I-tetrols), and then
measure the released tetrols byfluorescence inline with
RP HPLC and estimate the amount ofadduct from the
amount of tetrols recovered. Although fluorescence of
thetetrolsisdue tothe sameintact pyrenemoietyfound
in covalently bound BPDE, the interaction ofthe DNA
bases with covalently bound BPDE strongly quenches
the fluorescence of the pyrene moiety. Thus, indirect
measurement of adducts using tetrols is necessary to
achieve sensitivity with this technique. Application of
this approach to the detection of other carcinogens in
DNA clearly depends on the presence and the intact
release of a fluorescent moiety. Under the HPLC and
detection conditions of Rahn and co-workers (84), as
little as 31 fmole of BaP tetrols or one BP modification
per 107 bases in 100 ,ug DNAis theoretically detectable.
Advantage has been taken ofthe specificity and sen-
sitivity of antibody-antigen reactions to detect DNA
Table 3. Experimental models in which DNA adduct levels and persistence do not correlate with target organ specificity.
Tumor-"resistant" organ where Tumor-"sensitive" organ where fewer
Carcinogena adducts persistb adducts form and/or persist Persistence References
BaP C57BL/6 and DBA/2 mouse skincd Swiss mouse skin 48 hr (74)
24 hr (75)
MCPP DBA/2 mouse skind TO and C57/2 mouse skin 24 hr (76)
3-MC C57BL/6 and DBA/2d mouse skin Swiss mouse skin 48 hr (74)
DMBA C57BL/6 and DBA/2cd mouse skin Swiss mouse skin 8 days (74)
C57B1 mouse skin Swiss mouse skin 48 hr (54)
DMBA Sprague-Dawley rat liver Sprague-Dawley rat mammary 12 days (77)
gland
aAbbreviations given in footnote to Table 1.
bTotal covalent modification of DNA is measured to determine this relationship; in addition, for MCPP (see Table 1) and DMBA, but only
in Dipple et al. (54), the persistence of individual adducts was measured.
eSimilar levels of adducts persisted in organs which are resistant and sensitive.
dDBA/2 mice are more resistant to the tumorigenic effects of polycyclic aromatic hydrocarbons than are C57BL mice.
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Table 4. Assays for the detection of carcinogen-DNA adducts.
Modification of
Limit of detection, Amount of DNA used analyzed DNA,
Method fmole per analysis, ptga adducts/base
UV in line with HPLC
[major benzo(a)pyrene-DNA adductb] 100,00ff 2600 2 x 10-5
Fluorescence in line with HPLC
(BPDE-I-tetrol) 31d 100 1 x 10-7
Photon counting synchronous scanning fluorimetrye 1 x 10-6
Immunoassays
Polyclonal rabbit antibodies against
BPDE-I-DNA'
Competitive assays
RIA 5300V 1 1.7 x 10-3
ELISA 559 1 1.8 x 10-5
USERIA 129 1 3.9 x 10-6
USERIA 10 25 1.4 x 10-7
Noncompetitive assays
USERIA 3 0.01 9.7 x 10-5
Monoclonal antibodies against BPDE-I-DNAh
Competitive ELISA 199 0.005 1.2 x 10-3
Noncompetitive ELISA 3 0.0002 4.9 x 10-3
'P-postlabeling 0.03-0.a 1 1 x 10-7_10-8
aAs a guideline, 10-100 ,ug DNA is recoverable from 0.2-1 g tissue or the buffy coat of25-50 mL human blood.
bBenzo(a)pyrene is used as an example in this table since these techniques have been applied to the detection of its major adduct, 10-
(deoxyguanosin-N2-yl)-7,8,9-trihydroxy-7,8,9,10-tetrahydrobenzo(a)pyrene. cData ofWeinstein (83).
dData of Rahn et al. (84).
'Data of Vahakangas (85).
fData of Hsu et al. (86).
gThis amount of adduct shows 50% inhibition.
hData of Santella et al. (87).
'Data of Gupta (88).
Theoretical limit of detection.
adducts. Polyclonalrabbitantiserahavebeenraisedand
monoclonal antibodies produced against carcinogen-
modified DNAandmodified DNAand RNAcomponents
(Table5). Bothsmallalkylations andbulkymodifications
are included inthis list. Available antibodies specific for
carcinogen-modified DNA components have been re-
viewed elsewhere (103,104).
These antisera and antibodies havebeenusedinthree
types of immunoassays: radioimmunoassays (RIA) in-
cluding the radioimmunosorbent technique (RIST), en-
zyme-linked immunosorbent assays (ELISA), and
ultrasensitive enzymatic radioimmunoassays (USERIA).
As is evident from the summaries below, all of these
assays could be applied to the detection of chemical-
DNA adducts in human tissues.
Immunoassays may be executed in a competitive or
noncompetitive fashion. RIA are competitive assays
whereas solidphase assays maybeperformed according
to a competitive or noncompetitive protocol. In com-
petitive immunoassays, two chemically identical hap-
tens, one the tracer and the other an inhibitor, compete
under equilibrium conditions for the same antibody
binding site. When the concentration of the tracer is
constant, the concentration of the inhibitor is reflected
in the degree to which it inhibits binding of the tracer
totheantibody. Quantitationisbased onthecomparison
ofunknowns with aninhibition curve generatedby com-
peting increasing concentrations of standard unlabeled
hapten (104).
In RIA, although the haptens are chemically identi-
cal, one hapten is radiolabeled (the tracer) while the
other one is unlabeled (the inhibitor). In the conven-
tional RIA, performed in tubes, the antigen-antibody
complex is separated from the whole reaction mixture
by precipitation. After centrifugation or filtration (89),
the precipitate is counted to deternine the antigen level.
In solid phase assays (including ELISAs, USERIAs,
and RISTs), where the antigen is coated on a solid plas-
tic surface, antibodybindingtothe antigen is monitored
by binding a second antibody. The second antibody is
either linked to an enzyme which can cleave a chro-
mogen (p-nitrophenylphosphate) or a radioactive sub-
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Table 5. Monoclonal antibodies or polyclonal antisera directed
against carcinogen-modified DNA or DNA components.
Antigen or carcinogen Nature of antibody References
0-Methyldeoxyguanosinea Rabbit polyclonal (89)
Rabbit polyclonal (90)
Monoclonal (90)
06-Ethyldeoxyguanosinea Rabbit polyclonal (91)
Monoclonal (92)
06-isopropyldeoxyguanosinea Monoclonal (92)
06-butyldeoxyguanosinea Monoclonal (92)
Monoclonal (93)
04-ethyldeoxythymidinea Monoclonal (92)
04-butyldeoxythymnidinea Monoclonal (93)
02-butyldeoxythymidinea Monoclonal (93)
AAF_C8-dGb Rabbit polyclonal (94)
AAF-DNA Rabbit polyclonal (95)
(96)
BPDE-I-DNA Rabbit polyclonal (97)
BPDE-I-DNA Monoclonal (87)
BPDE-I-N2-dGb Monoclonal (87)
AFBI-DNA Monoclonal (98)
(99)
Cis-diamminedichloro- Rabbit polyclonal (100)
platinum (II)-DNA
Thymine dimer-DNA Monoclonal (101)
Thymine glycol-DNA Monoclonal (102)
aThe immunogen was the corresponding riboside complexed to
various carrier proteins.
bThese haptens were complexed to various carrier proteins to
elicit an immune response.
strate (3H-adenosine monophosphate) (105), or the
second antibody is labeled with 1 5I (e.g., 1251I-labeled
goat antirabbit IgG) (91). The initial antibody-antigen
reaction is amplified in the first two cases because one
molecule ofenzyme can react with many substrate mol-
ecules; in the third case, amplification is due to the high
specificactivityofthe iodinated second antibody. Bound
enzymatic activity or radioactivity is thus determined
by spectrophotometric assay ofp-nitrophenol or by ra-
diometric assay of 3H-adenosine or 1251-antibody-anti-
gen complexes.
In a noncompetitive assay, antiserum is reacted with
standard or unknown antigen samples only. The assay
is completed as described above and, finally, bound en-
zymatic activity or radioactivity is determined.
The sensitivity of different types of immunoassays
depends in part on the characteristics ofthe antiserum
or monoclonal antibody. Solid phase immunoassays are
generally more sensitive than, but at least as sensitive
as, RIA (86,91,105). Of the different solid phase im-
munoassays, USERIA is at least as sensitive as, ifnot
more sensitive than, ELISA (86,99,105).
For example, a typical RIA with polyclonal antisera
may detect tens of nanograms of adducts in 2 to 20 ,ug
of DNA (94,97). In competitive assays, using 1 ,ug of
DNA, the amounts of BaP-DNA adducts that showed
50% inhibition were 5300 fmole in RIA, 55 fmole in
ELISA, and 12 fmole in USERIA. As little as 3 fmole
adduct in 10 ng were detected by noncompetitive
USERIA, and as little as 10 fmole adduct in 25 ,ug DNA
were detected by competitive USERIA (approximately
1.3modifications in 10 bases) (86). Therefore, USERIA
is approximately 500-fold more sensitive than radioim-
munoassay and 5-fold more sensitive than ELISA for
detection of BaP-DNA adducts (86).
Byapplication ofhighlysensitiveinstrumentation, for
example for the measurement of fluorescent products
in ELISA assays, the sensitivity of the immunoassays
currently in use can be increased to theoretical limits
ofdetection ofone DNA adduct per cell orless (Poirier,
personal communication).
The advantages ofusing immunoassays as opposed to
other methods to detect carcinogen-DNA adducts in-
clude the ability to recognize adducts at levels probably
found in human DNA. Theoretically, the specificity of
the antigen-antibody reactions should permit detection
of one type of chemical adduct in DNA where many
types of adducts may persist. This is especially true of
monoclonal antibodies which are specific for usually a
single antigenic determinant. The reproducibility and
rapidity of performing immunoassays is also advanta-
geous for monitoring exposure to carcinogens in large
numbers of tissue samples. Perera et al. (106) demon-
strated that adducts present at low levels in human
tissues are detectable by immunoassay.
Alternative methods for adduct detection which do
not involve the use of radioactive carcinogens include
methods where nucleic acid monomers are chemically
orenzymatically derivatized with aradioactive reagent,
chromatographically separated, and fractions are as-
sayed for radioactivity. The chromatogram is compared
with chromatograms ofstandard derivatized adducts to
identify modifications in a DNA sample. When the ri-
bosyl ordeoxyribosyl moietyis derivatized, thesemeth-
ods are generally applicable to the detection of many
carcinogen-DNA adducts for which standards are avail-
able. These methods in principle also circumvent the
need for time-consuming development of special assay
reagents, such as antibodies, for each carcinogen.
One method ofthis type is32P-postlabeling, described
initially by Randerath and colleagues (107) and later by
Haseltine and coworkers (108), and discussed in detail
elsewhere in this issue (109). In this procedure, the
digestion of DNA to deoxynucleoside 3'-monophos-
phates precedes enzymatic phosphorylation of the 5'-
hydroxyl group with [gamma-32P]-ATP, chromato-
graphic separation ofthe labeled products, and assay for
radioactivity.
Randerath and his colleagues analyze the [5 _32p]
deoxynucleoside-3',5'-bisphosphates (32pdNps) by thin-
layer chromatography (TLC). Unmodified 'pdNps were
resolved by one- or two-dimensional TLC on a PEI-
cellulose plate. To resolve the modified 32pdNps, this
group adopted a four-dimensional thin-layer chroma-
tographyprocedure onPEI-celluloselayers (88) orPEI-
cellulose in combination with C18 reverse-phase layers
(110). Chromatography in buffer or buffer-organic mix-
tures (directions 1 and 2) afforded separation of inor-
gaic 32P-phosphate (a product ofthe unreacted [gamma-
P]-ATP) and unmodified 32pdNps from the modified
32pdNps. Carcinogen-DNA adducts were finally re-
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solved by chromatography in high salt, high urea sol-
vents (directions 3 and 4).
The advantages of postlabeling include: the obvious
lack ofrequirement for radioactive carcinogens; any an-
imalorhuman DNAsample canbescreened; manysam-
ples can be analyzed simultaneously; and the sensitivity
ofthe assayis, intheory, thehighest ofavailable adduct
assays. The sensitivity of the assay is based on the
availability of[gamma-32P]-ATP with a specific activity
much higher than the specific activity of available car-
cinogens: as high as 8000 Ci/mmole. In addition, since
32p emits high energy betaralys compared to the lower
energy rays emitted during 1 C and H decay, disinte-
gration can be easily detected on X-rayfilm. Since films
exposed to samples containing3P maybe developed for
extended periods and exposure may be enhanced with
an intensifying screen and/or in the cold, as little as 10
dpm in a 10 m2 area are detectable (111).
Using only PEI-cellulose TLC in the protocol de-
scribed above, Randerath and coworkers recovered ap-
proximately 50% of chromatographed adduct and have
detected approximately one aromatic adduct in 107 bases
using 1 ug ofDNA (88). When inorganic phosphate and
unmodified nucleotides were initially removed from the
postlabeling reaction mixture by RP-TLC, background
radioactivity was reduced further and, although recov-
eries were generally less than 50%, the lower limit of
detection calculated by these researchers was one ad-
duct in about 108 bases (110).
DNA modified in vitro and in vivo by different types
of carcinogens has been subjected to postlabeling ana-
lysis (64,88,110,112). This method can successfully de-
tect adducts of aromatic amine and amides, polycyclic
aromatic hydrocarbons and methylating agents.
In conclusion, there are a number of methods avail-
able to detect DNA adducts but only some ofthem are
applicable in their current forms to the detection of
adducts in human DNA samples. Each technique has
its own advantages and limitations; depending on the
specific objectives of monitoring projects, different
methods may prove to be advantageous for specific
purposes.
Use of DNA Adducts as Dosimeters:
Factors Affecting DNA Adduct
Levels
Analysis of human DNA for the presence of specific
adducts has been successful in at least two instances
using immunoassays (106,113-115). Using polyclonal
rabbit antiserum specific for BaP covalently bound to
DNA in an enzyme-linked immunosorbent assay, Per-
eraandcolleagues (106) establishedthatlungDNAfrom
BaP-treated rabbits ormice contained antigenicity. As-
sumingthis antigenicity was due to BaP adducts in DNA,
they detected as little as 0.08 to 0.1 frnole (45-57 fg)
adducts/microgram DNA. In the same system with the
same assumptions, these researchers detected low lev-
els (0.14-0.18 fmole or80-100fg) ofBaP-DNAadducts
in tissues from five of 27 patients. Adducts were de-
tected in DNA from tumorous lung tissue from four
patients, in DNA from nontumorous lung or bronchus
tissue from three patients, and in peripheral blood
mononuclear cell DNA in three patients.
Exposure histories were available for only 15 of the
27 cases, and the five positive samples were among those
cases for which histories were available. The five pos-
itive samples were from lung cancer patients who at
some time in their lives had smoked cigarettes or had
been exposed to smoking in the home (one individual).
Only one patient had smoked within three years prior
to surgery; this patientquittwomonthsbefore surgery.
No correlation, however, was observed between smok-
ing and the results of the immunoassays. One positive
case had been occupationally exposed to coal dust and
fumes. All positive cases and almost all negative cases
hadbeen exposedtourban airpollutionformostoftheir
lives. It is impossible, unfortunately, to draw substan-
tial conclusions from a study such as this one with a
small number of unselected cases and controls. These
preliminary results are encouraging, however, for the
possibility of detecting adducts in human tissues in a
more comprehensive study.
The feasibility of quantitatively assessing exposure
to chemicals using DNA adducts is the subject of this
conference. In addition to the availability of sensitive
methods to quantitate adducts, factors essential to de-
terminetheusefulness ofadducts as dosimeters include:
the rate of modification as a function of dose (due to
changes in metabolic paths with dose, induction or sat-
uration of specific and nonspecific DNA repair pro-
cesses, and similar dose-dependent processes); the ability
of the modification to reflect past or recent exposures
(i.e., the persistence of the modification, including
chemical stability and susceptibility to enzymatic re-
pair); andfinallytheabilityoftheparticularmodification
to reflect acute or chronic exposure to the parent chem-
ical (i.e., modification as a function of the number of
doses).
Usingtechniques ofmolecular epidemiology, adducts
havebeenquantifiedinanimalDNAandrelatedtodose,
as discussed above. Quantitative adduct analysis in hu-
man DNA to measure exposure, however, is more com-
plicated for several reasons. Individuals live in
environments where hazardous chemical contamination
is diverse and ill-defined, unlike controlled laboratory
experiments. Thus, human doses are complex and not
easily determined. Most carcinogens require metabolic
activation prior to DNA modification. Metabolic capac-
ity is determined genetically as well as environmentally
andtherefore variesbetweenindividuals(116), between
tissues (117), andbetweendifferentsections ofthe same
tissue (118). The magnitude of differences is greatest
between individuals, and outbred animals vary over a
wider range than inbred animals (114,119). People,
therefore, might vary extensively in adduct formation
with respect to environmental dose. Variations in ad-
duct formation has been demonstrated using organ ex-
14DOSIMETRY OF EXPOSURE TO GENOTOXIC CHEMICALS 15
plants: benzo(a)pyrene modification of human DNA
varied 50-to200-fold in colon (118), bladder (120), bron-
chi (121), and esophagus (122); other species showed
less variation than humans in covalent BaP binding to
DNA (123). Similarindividual variations were observed
with the binding of other carcinogens to these and ad-
ditional organs in culture (114).
The kinetics and the extent of DNA adduct removal
inhumantissues invivo areunknown. Thereisevidence
forDNArepairinculturedhumancells (124) andhuman
tissue extracts (125). DNA repair capacities, however,
may well vary in vivo in different organs and between
individuals. Unpredictable and variable rates of DNA
repairwouldmakeitdifficulttoextrapolatetheamounts
of adducts in DNA at one time from the amount of
adducts left in DNA at some later time. Furthernore,
the qualitative and quantitative profiles ofchemical-DNA
adducts formed in people may be different from the
proffles ofadducts already identified in animal DNA. Of
particular importance, the biologicallyrelevant adducts
may be as yet unidentified minormodifications ofDNA.
Ifadduct profiles are qualitatively different, structural
identification ofadducts inhuman DNAwillbe asizable
task. Results to date indicate, however, that adducts
produced in human organ culture after treatment with
different carcinogens (includingBaP, AFB1, DMBAand
DMH) are the same adducts identified in experimental
animals (114,118,122,126). Assuming the profile ofmet-
abolic enzymes does not change radically early in organ
culture (when the adducts in these experiments were
identified), it is likely the same adducts form in vivo in
people.
Given that adduct repair and persistence in vivo in
humansisunknown, theintervalbetween exposure and
sampling might be critical. If human cells are highly
effective inDNArepair, adducts, althoughformed, may
goundetected. Detection ofadducts inhuman DNAwill
also depend on the rate of cell turnover in the tissue
used to monitor adduct formation. If cells replicate
quickly, then only short-tern exposures could be meas-
ured in this tissue. Both ofthese considerations would
be strongly affected by the time interval between ex-
posure and sampling oftissue for analysis. Finally, the
usefulness of adducts a dosimeters depends on the fi-
delity of the surrogate cell DNA as an index of target
cell exposure.
Thus, although the interpretation ofadduct levels as
dosimeters remains complicated, adducts can serve as
useful qualitative markers of exposure. As more infor-
mation is learned about adduct kinetics in DNA of hu-
man tissues as well as other factors mentioned above,
DNA adducts may become more useful as dosimeters.
In addition, further study ofthe fornation ofDNA ad-
ducts in human tissue will provide further insight into
factors determining how people respond to exposure to
chemicals.
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